AstraZeneca’s Trastuzumab deruxtecan therapy receives CDSCO nod to manage HER2- low & ultra-low…
The medicine is now indicated as a monotherapy for the treatment of adult patients with unresectable or metastatic breast cancer
Recover your password.
A password will be e-mailed to you.
Recover your password.
A password will be e-mailed to you.